I see Tiziana Life Sciences, the London and US-listed biopharmaceutical group, today confirmed the snippet on Betaville earlier this week. Below is the link in case you missed it:..
Posts tagged: Tiziana Life Sciences
Tiziana Life Sciences is making a return to these pixels as Betaville hears there could some fresh news announced in the next few days about the company's development of a therapeutic treatment to combat Covid-19 variants.
The talk is the company's nasal drug therapy may participate in another trial in Brazil with hopes that once that it is completed the treatment could prove to work against variants, such as the Delta variant...
Punters might want to keep an eye on Tiziana Life Sciences, the London-listed biopharmaceutical company.
That's because Betaville hears the company has been working on a Covid-19 drug treatment that might be able to address the new variants of the virus entering the United Kingdom...
The buzz around Tiziana Life Sciences, the London listed biopharmaceutical company, might have subsided for a few weeks but it hasn't gone away.
Indeed, the company released a couple of statements this morning about some of its treatments it is developing. Below are the links:..
Betaville is still watching Tiziana Life Sciences. Why?
Well, the mutter is the Aim-listed biotechnology company is close to figuring out a way to increase liquidity through some corporate action.
And this could be happening sooner rather later.....
It seems some readers were paying attention to Monday's note on Tiziana Life Sciences, the Aim-listed biotechnology company.
The shares have almost closed the gap with the US line, up over 20pc in the last couple of days......
Remember Tiziana Life Sciences, the biotechnology company?
For some reason the Aim-listed shares are trading at around 30pc discount to the US-listed ADRs.
I'm not sure why but presumably that discount won't last for too long?.....
Investors that have taken a punt on Tiziana Life Sciences in recent weeks were nicely rewarded today after the shares closed up almost 27pc.
In part, the shares surged because the company - which is working on treatments for a variety of diseases, including Covid 19 - was awarded a key patent.
Below is the link to today's announcement in case you missed it:..
It's that time of the week when Betaville writes about Tiziana Life Sciences, the Aim-listed biopharmceutical developer.
Well, readers might recall that last Friday I suggested there are all sorts of things brewing at Tiziana Life Sciences.
And I understand some fresh data could emerge in the next week that could be transformational for the business, making Tiziana Life Sciences of interest to the pharmaceutical giants...
So, Betaville suspects this note (see below) from HC Wainwright & Co is what all the fuss was about on Friday. The company has also this morning sacked Shore Capital and replaced the firm with Optiva as its broker...
Betaville expects Tiziana Life Sciences will see a fresh round of interesting developments over the next couple of days.
Indeed, one thing to look out for will be another presentation of StemPrintER, Tiziana's breast cancer test, at the ASCO conference this afternoon. Below is a link to this morning's announcement:..
So, Tiziana Life Sciences has this morning unveiled the "major corporate activity" Betaville was expecting over the next couple of weeks.
It's a bit earlier than I expected but the top line details are a demerger of StemPrintER. Below is a link to this morning's statement:..
The buzz around Tiziana Life Sciences grows louder.
This is because there is talk circulating the market the company could be involved some major corporate activity over the next couple of weeks.
However, don't expect an imminent takeover bid for the whole business from Exact Sciences Corporation. That seems unlikely for a while, said people following the situation...
Small cap enthusiasts will be watching to see how shares of Aim-listed Tiziana Life Sciences reacts this morning after its US ADR stock shot up 10pc on Friday evening on large volume.
Last week, Tiziana unveiled the details of a Royal Marseden trial for StemPrintER, its stem cell biology-based genomic tool for the prediction of disease recurrence in breast cancer patients, at the ASCO conference...
There will be plenty of small cap punters watching Tiziana Life Sciences this morning after it released details of a new study on StemPrintER, its stem cell biology-based genomic tool for the prediction of disease recurrence in breast cancer patients, at the ASCO conference last night.
Below is a link to an interview with Tiziana's chief executive Gabriele Cerrone, who has been working on the test over the last seven years...
I have had a few enquiries about whether Tiziana's new new combinational therapy was the one announced just a few hours after the publication of Betaville's piece on Monday.
People familiar with the matter have confirmed the announcement on Monday lunchtime is the new combinational therapy referred to in my piece on Monday. I have pasted the link to the company announcement below:..
Betaville is expecting another update from Tiziana Life Sciences in the next couple of days about its product for the fight against Covid-19
People following the situation said Tiziana is due to unveil a new combinational therapy to treat Covid-19 using a well-known FDA approved drug.
Small cap enthusiasts might want to keep an eye on Aim-listed Tiziana Life Sciences.
Word reaches Betaville that the company has developed a unique approach for the fight against Coronavirus.
In case you don't recall Tiziana's shares soared over 200pc last month during one trading session after it launched plans to fastrack a drug it thinks could treat some of the more severe symptons of Coronavirus...